MPX Bioceutical Corporation announced that Robert Petch has joined the board of directors of MPX. Mr. Petch has over 30 years of experience in management, strategic planning and financial analysis. With experience on both the buy-side and sell-side of the investment market, Mr. Petch will be a valuable asset on the execution of MPX's on-going strategy of growth in the North American cannabis industry. Mr. Petch worked for 15 years at Dresdner Kleinwort Benson advising companies on strategy, fund-raising including IPOs where he led a number of successful issues, acquisitions (public and private), disposals and other market-related issues. More recently, he spent 4 years assessing investment opportunities for a specialist AIM-listed private equity investment company and a further 4 years advising a substantial family office on its private equity and real estate portfolio before going independent in 2014.